Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.700-0.750 for the period, compared to the consensus earnings per share estimate of 0.705. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion.
Amneal Pharmaceuticals Trading Up 4.0%
NASDAQ AMRX traded up $0.33 on Friday, reaching $8.54. 2,392,267 shares of the company were exchanged, compared to its average volume of 1,359,587. The business's fifty day moving average price is $8.03 and its 200 day moving average price is $7.96. The stock has a market capitalization of $2.68 billion, a P/E ratio of 854.85 and a beta of 1.11. Amneal Pharmaceuticals has a fifty-two week low of $6.68 and a fifty-two week high of $9.48.
Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Equities research analysts forecast that Amneal Pharmaceuticals will post 0.53 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on AMRX shares. Wall Street Zen lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. The Goldman Sachs Group assumed coverage on Amneal Pharmaceuticals in a research note on Friday, June 6th. They set a "buy" rating and a $12.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $11.60.
View Our Latest Report on Amneal Pharmaceuticals
Institutional Investors Weigh In On Amneal Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Amneal Pharmaceuticals by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company's stock valued at $793,000 after purchasing an additional 4,178 shares during the period. Creative Planning raised its holdings in shares of Amneal Pharmaceuticals by 61.9% in the 2nd quarter. Creative Planning now owns 23,896 shares of the company's stock valued at $193,000 after buying an additional 9,136 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Amneal Pharmaceuticals by 5.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company's stock valued at $2,807,000 after buying an additional 16,536 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Amneal Pharmaceuticals in the 1st quarter valued at $244,000. Finally, Millennium Management LLC raised its holdings in shares of Amneal Pharmaceuticals by 32.6% in the 1st quarter. Millennium Management LLC now owns 2,087,398 shares of the company's stock valued at $17,492,000 after buying an additional 512,842 shares during the period. Hedge funds and other institutional investors own 31.82% of the company's stock.
About Amneal Pharmaceuticals
(
Get Free Report)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Featured Articles
Before you consider AMNEAL PHARMACEUTICALS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AMNEAL PHARMACEUTICALS wasn't on the list.
While AMNEAL PHARMACEUTICALS currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access